Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections

Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension

(2015) Urshila Durani et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies

(2015) Aaron Cumpston et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis

(2015) Marisa H. Miceli et al.   MYCOSES

Phase 1b Study of New Posaconazole Tablet for Prevention of Invasive Fungal Infections in High-Risk Patients with Neutropenia

(2014) Rafael F. Duarte et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Switching from Posaconazole Suspension to Tablets Increases Serum Drug Levels in Leukemia Patients without Clinically Relevant Hepatotoxicity

(2014) Dong Sik Jung et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multicenter Study of Posaconazole Therapeutic Drug Monitoring: Exposure-Response Relationship and Factors Affecting Concentration

(2012) Michael J. Dolton et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Single-Dose Phase I Study To Evaluate the Pharmacokinetics of Posaconazole in New Tablet and Capsule Formulations Relative to Oral Suspension

(2012) Gopal Krishna et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome

(2012) J. J. Vehreschild et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers

(2012) G. Krishna et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America

(2011) Alison G. Freifeld et al.   CLINICAL INFECTIOUS DISEASES

Invasive fungal disease in patients treated for newly diagnosed acute leukemia

(2010) Sarah P. Hammond et al.   AMERICAN JOURNAL OF HEMATOLOGY

Pharmacokinetic/Pharmacodynamic Profile of Posaconazole

(2010) Yanjun Li et al.   CLINICAL PHARMACOKINETICS

Exposure–Response of Posaconazole Used for Prophylaxis Against Invasive Fungal Infections: Evaluating the Need to Adjust Doses Based on Drug Concentrations in Plasma

(2010) S H Jang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Factors Influencing Pharmacokinetics of Prophylactic Posaconazole in Patients Undergoing Allogeneic Stem Cell Transplantation

(2009) V. Kohl et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Omeprazole Significantly Reduces Posaconazole Serum Trough Level

(2009) Jan‐Willem C. Alffenaar et al.   CLINICAL INFECTIOUS DISEASES

Pharmacokinetics and Absorption of Posaconazole Oral Suspension under Various Gastric Conditions in Healthy Volunteers

(2008) G. Krishna et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications

(2008) D. Andes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies

(2008) Jutta Auberger et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY